Marston NA, Giugliano RP, Im K, et al. - Given that no consistent reductions in cardiovascular events are discerned in randomized trials of therapies that primarily lowered triglycerides, a systematic review and trial-level meta-regression analysis was performed of 3 classes of lipid-lowering therapies that decrease triglycerides to a higher extent than they do low-density lipoprotein cholesterol (LDL-C): fibrates, niacin, and marine-derived omega-3 fatty acids. From 24 trials of nonstatin therapy, researchers assessed a total of 197,270 participants with 25,218 major vascular events and from 25 trials of statin therapy, they assessed 177,088 participants with 20,962 major vascular events. Analysis of data from these randomized controlled trials revealed an association of triglyceride-lowering with a lower risk of major vascular events, even after adjustment for LDL-C lowering. This effect is, however, less than that for LDL-C and also the effect attenuated on the exclusion of the Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial. Furthermore, marine-derived omega-3 fatty acids, particularly high-dose eicosapentaenoic acid, appear to have benefits that exceed their lipid-lowering effects.